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doi:10.1016/j.gmbhs.2011.08.004Abstract Gastrointestinal stromal tumors (GISTs) are usually solitary tumors, mostly situated
in the stomach and proximal small intestine. The existence of multiple lesions is thought to be
an unusual event in some specific circumstances. Synchronous lesions are commonly viewed as
the result of metastatic GIST, especially when the tumors are very different from each other in
size and smaller lesions are located on the omentum or peritoneum. Nevertheless, differential
diagnosis should include multiple primary sporadic GIST. Here we report a rare sporadic meta-
chronous double GIST of the stomach; both tumors lacked KIT and PDGFRA mutations. The
76-year-old male underwent wedge resection of both gastric tumors and was treated postoper-
atively with imatinib 400 mg daily. He remained recurrence-free after 20 months of follow-up.
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Gastrointestinal stromal tumors (GIST) are now thought to
arise from transformed neoplastic precursors of intestinal
cells of Cajal (ICCs). KIT is expressed in approximately 95%
of GISTs. Approximately 80% of GISTs have KIT gene muta-
tions, and consequently activate the different domains of
the KIT receptor. Nearly 75% of KIT gene mutations in GISTrker Society. Published by Elsevier Taiwan LLC. All rights reserved.
82 T.-C. Yin et al.affect exon 11 and result in spontaneous dimerization and
activation of receptors.1e3
Activating mutations in the related platelet-derived
growth factor receptor alpha (PDGFRA) represent a subset
of GISTs that lack KIT mutations.4e6 In an analysis of 1105
GIST cases, 7.2% of tumors had PDGFRA mutations.7 Histo-
pathologically, KIT-negative GISTs, which may harbor
PDGFRA mutations, have some distinguishing features: they
are more often of the epithelioid type and are more
commonly found in the omentum and mesentery. GISTs
with wild-type KIT and PDGFRA genes accounted for only
15% of cases in a Norwegian investigation.8
It is still not conclusive whether the presence or absence
of KIT gene mutations affects GIST prognosis. Patients with
exon 11 mutations are more sensitive to imatinib than those
with or without other mutations. This advantage is gener-
ally not influenced by the imatinib dose. On the contrary,
when a higher dose of imatinib (800 mg vs. 400 mg) is
prescribed, patients with exon 9 mutations may experience
better disease-free survival. Moreover, not all activating
PDGFRA mutations are biologically equivalent. Sensitivity
to imatinib is uncertain because some PDGFRA mutations
are refractory to the agent, whereas others result in
a better outcome.5e7 Thus tyrosine kinase inhibitor (TKI)
treatment should always be attempted for metastatic
disease, even if the tumors are detected to have wild-type
KIT but PDGFRA mutations.
Multiple GISTs are mostly thought to be metastatic from
one main tumor, especially when the size varies signifi-
cantly from one tumor to another or when the minor tumors
are located in the omentum or mesentery. However,
primary GIST tends to be multicentric under rare specific
circumstances such as familial GIST, Carney triad, and
neurofibromatosis type 1 (NF1). Multiple sporadic GISTs are
entities that are hardly ever discussed in the literature.Case report
A 76-year-old male presented with dull and persistent
epigastric pain for several days, and an abdominal CT in
April 2009 showed an encapsulated lesion at the antrumFigure 1 (A) Computed tomography of a double gastric exophyt
(B) Both the tumors are well circumscribed. Marked calcification oand another calcified tumor over the upper gastric body
(Fig. 1). He reported that he had not experienced anorexia,
nausea, vomiting, hematochezia or hematemesis. Esoph-
agogastroduodenoscopy revealed two distinct submucosal
tumors over the antrum and fundus (Fig. 2). His history
revealed that he underwent an endoscopy examination in
2000 for tarry stool passage. Apart from a gastric ulcer, an
antral submucosal tumor was observed that was identical to
the antral submucosal tumor found this time. The tumor
size had increased slightly over the intervening 9 years.
The patient underwent surgery 3 months later for wedge
resection of the two gastric submucosal masses, which
measured 7.2  7  5.5 cm3 and 3.8  3.5  3.7 cm3,
respectively (Fig. 3). The fundal tumor was well circum-
scribed, with central necrosis and hemorrhage. Microscop-
ically, the fundal tumor was composed of epithelioid tumor
cells, while the antral tumor was composed of mixed
spindle and epithelioid tumor cells (Fig. 4). The mitotic
count for both tumors was <5/50 HPF. Immunohis-
tochemically, the cells of both tumors were positive for
CD117, CD34 and S-100 protein, and negative for smooth
muscle actin. The fundal and antral tumors both fell on
GISTs, NIH intermediate risk (5e10 cm, mitosis 5/50 HPF).
The resection margins of both tumors were negative for
malignancy grossly and histologically.
Tumor DNA from the two GISTs was extracted from
paraffin block sections and subjected to PCR amplification
for exons 9, 11, 13, and 17 of the KIT gene and exons 10, 12,
14, and 18 of the PDGFRA gene. These amplicons were then
sequenced. The results showed no detectable mutations in
these eight exons for either GIST. The patient was treated
postoperatively with the TKI imatinib 400mg daily and was
regularly followed up in our outpatient department.Discussion
Familial GIST shows a tendency to multiplicity. It is a rare
autosomal dominant genetic disorder and affected patients
sometimes present with skin hyperpigmentation (64%),
dysphagia (32%) or GI autonomic nerve tumors such as par-
agangliomas. Several kindreds with heritable mutations inic tumor over the antrum (star) and upper body (thick arrow).
f the fundal tumor is evident.
Figure 2 (A) Submucosal tumor of the gastric antrum. (B) Submucosal tumor with bridging folds in the fundus. (C) Endoscopic
ultrasonography (EUS) shows that the lesion arises from the muscle layer.
Multicentric GIST with wild-type KIT and PDGFRA 83different domains of the KIT gene have been reported.9e11
Pathologically, extensive involvement of the GI tract and
diffuse ICC hyperplasia directly adjacent to the main tumor
are characteristics of familial GIST.
The coexistence of GIST and paraganglioma is termed
CarneyeStratakis syndrome. Germline mutations in the
succinate dehydrogenase (SDH) subunit genes (in the
absence of KIT or PDGFRA mutations) are oncogenic for
these autosomal-dominant hereditary syndromes. When
pulmonary chondroma is associated with CarneyeStratakis
syndrome, this is termed the Carney triad. The mostFigure 3 Gross image of the two resected gastric submucosal
tumors at the fundus (left) and antrum (right) measuring
7.2  7  5.5 cm3 and 3.8  3.5  3.7 cm3, respectively.frequent change is deletion in 1q12eq21, a region that
harbors the SDHC gene. Another frequent change is loss of
1p.12,13 When compared with sporadic gastric GIST, gastric
stromal tumor in the Carney triad shows distinctive
features: younger onset, bias in females, multiplicity,
epithelioid cell type ascendency, serial tumor occurrence,
frequent lymph node metastasis, and unpredictable
behavior. Thus, a gastric stromal tumor in the Carney triad
differs from sporadic gastric GIST clinically, pathologically,
and behaviorally.14 From this perspective, GIST can be
caused by impaired mitochondrial oxidation, and patients
with GIST that are negative for KIT and PDGFRA mutations
do not respond well to treatment with tyrosine kinase
inhibitors and may have CarneyeStratakis syndrome or
Carney triad.15e17 For TKI-unresponsive GIST, succinate
dehydrogenase is possibly a new molecular target in the
future.
Another situation in which GIST tends to be multicentric
is NF1-related GIST. GISTs are increasingly being recognized
in association with NF1. NF1-related GISTs mostly have no
KIT or PDGFRA mutations. Somatic inactivation of the wild-
type NF1 allele in the tumor may lead to GIST development
in this patient group. In addition, inactivation of neuro-
fibromin is an alternative mechanism that induces hyper-
activation of the MAP kinase pathway. Thus, the molecular
pathogenesis of GIST in NF1 patients indicates that this type
of tumor might be a clinical symptom in NF1.18e20 Except
for multiplicity, GISTs in NF1 also exhibit a disposition to
younger onset, are mostly found in the jejunum or ileum,
are small and mitotically inactive, and have better prog-
nosis compared with sporadic GIST.21 Focal or mild hyper-
plasia of ICCs is observed in this patient group. Patients
with NF1-related GIST of high or intermediate risk should
Figure 4 Low-power field images of (A) (fundus) and B (antrum) show the low power fields of GISTs. The arrows in A indicate
hemorrhage and necrosis in the fundal tumor (hematoxylin & eosin stain; original magnification 20). The tumor cells are of
epithelioid subtype in the fundus (C) and of mixed spindle and epithelioid type in the antrum (D) (hematoxylin & eosin; original
magnification 400). The inset shows immunohistochemical CD117 expression (original magnification 400).
84 T.-C. Yin et al.not be eligible for adjuvant imatinib therapy because of
poor therapeutic responses.22
Except for these unusual conditions, multiple primary
tumors actually represent a significant fraction of multi-
focal GISTs, which implies that ICCs in such individuals are
primed for transformation in some way. Agaimy et al found
clustering of multiple GISTs in the proximal stomach, close
tumor proximity, and different KIT mutations in various
lesions from the same patient, possibly as a result of an
unidentified field effect.23 Thus, multiple primary GISTs
may occur with different sizes, locations, morphology and
risk categories.24 Therefore, differential diagnosis of GIST
metastasis or recurrence should include the occurrence of
multiple primary GISTs, even when the sizes vary from each
other significantly or when the minor tumors are located in
the omentum or mesentery.25
GISTs in NF1 and the Carney triad and pediatric tumors
generally lack KIT and PDGFRA mutations. Wild-type KIT
and PDGFRA GISTs in these situations are mostly refractory
to TKI therapy. In our case, no family history of GI tract
malignancy was recorded, and no paraganglioma, neurofi-
bromatosis or cafe´-au-lait spots were found during a thor-
ough physical examination. The lack of direct evidence of
identical genetic mutations in both gastric GISTs means that
it is difficult to discriminate between metastatic GIST and
double primary tumors. However, according to the
patient’s history, double gastric GISTs are more likely than
metastatic lesions because of the metachronous manner in
which the tumors occurred (the antral tumor was found
earlier and was slow-growing; the fundal tumor grew more
rapidly and was larger in size on resection). We believe thatour case is a rare sporadic multiple GIST with wild-type KIT
and PDGFRA, which is seldom reported. There is no final
conclusion on the therapeutic outcome of TKI after en bloc
resection of multiple GIST with wild-type KIT and PDGFRA.
In our case, the patient remained recurrence-free after 20
months of follow-up.
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